Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Shenqi Pharmaceutical Investment Management Co's revenue for the
three
months ended in Mar. 2026 was ¥423 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1,895 Mil.
Shanghai Shenqi Pharmaceutical Investment Management Co's Revenue per Share for the
three
months ended in Mar. 2026 was ¥0.66.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥3.31.
Warning Sign:
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd revenue per share has been in decline over the past 3 years.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Shanghai Shenqi Pharmaceutical Investment Management Co Revenue Related Terms
Shanghai Shenqi Pharmaceutical Investment Management Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co Revenue Chart
Shanghai Shenqi Pharmaceutical Investment Management Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shenqi Pharmaceutical Investment Management Co Revenue vs Drug Manufacturers Industry
Shanghai Shenqi Pharmaceutical Investment Management Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,895 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) has a Revenue of ¥1,895 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors.
Is Shanghai Shenqi Pharmaceutical Investment Management Co's Revenue too high?
Shanghai Shenqi Pharmaceutical Investment Management Co's current Revenue is ¥1,895 Mil. Overall, Shanghai Shenqi Pharmaceutical Investment Management Co has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shenqi Pharmaceutical Investment Management Co's Revenue compare to LLY and JNJ?
Shanghai Shenqi Pharmaceutical Investment Management Co's Revenue of ¥1,895 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Shanghai Shenqi Pharmaceutical Investment Management Co and its competitors. Shanghai Shenqi Pharmaceutical Investment Management Co's current Revenue is ¥1,895 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shenqi Pharmaceutical Investment Management Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥5.41, compared to a current price of ¥4.86 — trading 10.2% below its estimated fair value. The current Revenue is ¥1,895 Mil. Shanghai Shenqi Pharmaceutical Investment Management Co's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613), the current Revenue is ¥1,895 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shenqi Pharmaceutical Investment Management Co (SHSE:600613) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shenqi Pharmaceutical Investment Management Co stock appears to be undervalued.
The current stock price of ¥4.86 is trading 10.2% below its estimated GF Value™ of ¥5.41.
GuruFocus considers Shanghai Shenqi Pharmaceutical Investment Management Co to be Modestly Undervalued.
Key valuation signals for SHSE:600613:
Revenue: ¥1,895 Mil
GF Value™: ¥5.41 vs. price of ¥4.86 (10.2% below fair value)
No single metric tells the full story. See the SHSE:600613 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shenqi Pharmaceutical Investment Management Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600613 has been successfully added to your 
